Free Trial
NASDAQ:BCTX

Briacell Therap 6/14/2024 Earnings Report

Briacell Therap logo
$4.15 +0.08 (+1.97%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$4.15 0.00 (0.00%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Briacell Therap EPS Results

Actual EPS
$16.50
Consensus EPS
-$82.50
Beat/Miss
Beat by +$99.00
One Year Ago EPS
N/A

Briacell Therap Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Briacell Therap Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Briacell Therap Earnings Headlines

I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
See More Briacell Therap Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Briacell Therap? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Briacell Therap and other key companies, straight to your email.

About Briacell Therap

Briacell Therap (NASDAQ:BCTX)eutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

View Briacell Therap Profile